Swiss pharmaceutical company Novartis has filed a lawsuit against President Joe Biden's administration over a disagreement regarding the 340B Drug Discount Program. The company claims that the U.S. Health Resources and Services Administration interpreted a federal law wrongly, preventing Novartis from changing payment terms for participating hospitals. This move by Novartis could have significant repercussions on the negotiation process for the company's popular heart drug, Entresto, and its pricing under Medicare. Stay updated on market-moving news with TheFly and check out top-performing stocks on TipRanks.
Novartis Sues Biden Administration Over 340B Drug Discount Program
Swiss pharmaceutical giant Novartis has filed a lawsuit against the Biden administration over a disagreement regarding the 340B Drug Discount Program. The company claims that the U.S. Health Resources and Services Administration (HRSA) interpreted a federal law wrongly, preventing Novartis from changing payment terms for participating hospitals.
The 340B Drug Discount Program is a federal program that was established in 1992 to provide discounted prescription drugs to low-income and uninsured patients. Hospitals that participate in the program are required to pass along the discounts they receive from drug manufacturers to patients.
Novartis argues that the HRSA has misinterpreted the 340B law by requiring drug manufacturers to provide discounts to hospitals regardless of whether the drugs are actually used to treat low-income or uninsured patients. The company says that this interpretation of the law has led to "significant overpayments" to hospitals and that it has been forced to subsidize the program with its own profits.
The lawsuit could have significant repercussions on the negotiation process for Novartis's popular heart drug, Entresto. The drug is currently covered under Medicare Part D, and Novartis is seeking to change the payment terms for Entresto in order to increase its profits. The lawsuit could delay or prevent Novartis from making these changes, which could impact the price of Entresto for Medicare beneficiaries.
Background
The 340B Drug Discount Program was created as part of the Omnibus Budget Reconciliation Act of 1990. The program was originally designed to help hospitals that serve a disproportionate share of low-income and uninsured patients. The program has since been expanded to include a wider range of hospitals, including many that do not serve a disproportionate share of low-income and uninsured patients.
In 2010, the Affordable Care Act made significant changes to the 340B program. The changes included adding new eligibility requirements for hospitals and increasing the discounts that drug manufacturers are required to provide.
Top 5 FAQs
1. What is the 340B Drug Discount Program?
The 340B Drug Discount Program is a federal program that requires drug manufacturers to provide discounts to hospitals that serve a disproportionate share of low-income and uninsured patients. The program is designed to help these hospitals provide affordable prescription drugs to their patients.
2. What is Novartis's lawsuit about?
Novartis is suing the Biden administration over the HRSA's interpretation of the 340B law. Novartis argues that the HRSA is requiring drug manufacturers to provide discounts to hospitals regardless of whether the drugs are actually used to treat low-income or uninsured patients.
3. What could the lawsuit mean for Novartis?
The lawsuit could delay or prevent Novartis from making changes to the payment terms for its popular heart drug, Entresto. This could impact the price of Entresto for Medicare beneficiaries.
4. What could the lawsuit mean for the 340B program?
The lawsuit could have a significant impact on the 340B program. If Novartis is successful in its lawsuit, it could lead to changes in the way that the program is administered. This could make it more difficult for hospitals to participate in the program or could reduce the discounts that hospitals receive from drug manufacturers.
5. What is the future of the 340B program?
The future of the 340B program is uncertain. The program has been the subject of ongoing debate, with some stakeholders arguing that it is too costly and that it does not effectively target low-income and uninsured patients. However, the program remains popular with hospitals and patient advocates, and it is likely to continue to be a source of controversy in the years to come.
Civil Aviation Minister Ram Mohan Naidu has placed the blame on IndiGo for the widespread disorder and disruption in its operations, citing the airline's mismanagement of crew under new FDTL regulations. The Ministry has granted IndiGo a temporary exemption from FDTL norms in order to restore normalcy. Naidu also revealed that a committee has been formed to investigate the extent of the failure and hold those responsible accountable. However, the government's top priority remains mitigating the situation and supporting affected passengers while ensuring safety standards are not compromised.
In a major move, Netflix has announced its plans to acquire Warner Bros., HBO, HBO Max, and other related studios from Warner Bros. Discovery. With this deal valued at a whopping $82.7 billion, Netflix aims to expand its content library, increase theatrical film releases, and strengthen its global presence. The merger is expected to bring in annual savings of $2 billion to $3 billion and is set to benefit shareholders, subscribers, and the entire entertainment industry. However, it remains to be seen how this will affect consumers of Netflix and HBO Max, both of which are popular streaming services in the U.S.
In a historic move, Netflix has announced plans to purchase Warner Bros. Discovery in a deal worth $82.7 billion, including debt. The acquisition would make Netflix even bigger in the streaming market, with more than 300 million subscribers. This move also signals the growing influence of tech companies in the entertainment industry, as Netflix becomes the first major legacy studio to fall to a Silicon Valley competitor. The deal would also allow Netflix to continue its theatrical releases, something it had previously avoided. This unexpected move has sent shock waves through Hollywood and the broader media landscape.
In the midst of chaos and disruptions in flights, IndiGo CEO Pieter Elbers has been named as India's Best CEO by Fortune India. Despite the challenges, Elbers has successfully navigated IndiGo through an uncertain environment and has taken several measures to address the issue, including increased customer communication and addressing their needs. With the support of the civil aviation ministry and DGCA, Elbers hopes to return to a "full normal situation" by December 10-15, providing relief to affected passengers.
IndiGo, India's largest private sector airline, is facing major disruptions as daily cancellations reach up to 200 flights. The airline's operations have been severely hit, with over 1,000 cancellations in the span of 36 hours. The chaos has left passengers stranded and angry, with several major airports experiencing cancellations and delays. Questions are now being raised about IndiGo's dominance and potential monopoly in the country's aviation sector.
Air India, owned by Tata Group, came under scrutiny after operating an A320 neo plane without a valid Airworthiness Review Certificate (ARC) for many flights in November. The Directorate General of Civil Aviation (DGCA) and the airline have launched investigations, with concerned employees being de-rostered until further notice. The airline has acknowledged the seriousness of the issue and is working to identify and eradicate any deficiencies in their system.
The Directorate General of Civil Aviation (DGCA) has announced a relaxation in Flight Duty Time Limit (FDTL) norms in order to ease the operational disruptions faced by airlines like IndiGo. The change now allows pilots' leave to be counted as rest, overturning the previous rule of no substitution for weekly rest. This decision comes amid IndiGo's continuous cancellations, sparking concerns over passenger safety and political concerns. However, the Airline Pilots Association (ALPA) has raised objections to the selective relaxations given to IndiGo, stating it compromises safety. Despite these challenges, DGCA has urged for collective support from pilots to ensure safe and reliable air travel for passengers.
Maharashtra Chief Minister Devendra Fadnavis launched the Mumbai Metropolitan Region Development Authority's (MMRDA) Urban Tunnel project, which is estimated to cost Rs 8,056 crore. The 9.96-kilometre tunnel will connect Orange Gate to Marine Drive, reducing the travel time between the two locations to just 10 minutes. It will also ease traffic and provide relief to commuters, as it passes under approximately 700 properties and goes 50 meters below Metro-3.
IndiGo, one of India's leading airlines, delivered its strongest public apology yet for the nationwide disruptions that have plagued its operations over the past few days. The airline acknowledged the immense inconvenience and distress caused to thousands of passengers, and announced that they will receive full refunds and waivers on rescheduling requests. IndiGo also stated that they are working closely with authorities to stabilize operations, and urged customers not to travel to airports if their flights have been cancelled. Despite the current crisis, the airline assured customers that they are striving to earn back their trust and restore their reputation for reliability.
Vivo has finally released its highly anticipated X300 series in India, consisting of the Vivo X300 and X300 Pro smartphones. Both models, powered by the powerful MediaTek Dimensity 9500 chipset, are equipped with a 50-megapixel front camera. The X300 and X300 Pro differ in terms of battery capacity, with the latter boasting a larger 6,510mAh unit. Pre-booking for the smartphones is now open and they will officially hit the market on December 10, along with the optional Vivo Zeiss telephoto extender kit priced at Rs 18,999. Moreover, users can enjoy attractive introductory benefits from Vivo.